Clinical trials: Small Cell Lung Carcinoma (SCLC)
Carcinoma, Non-Small-Cell Lung
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
This is a research study to test the effectiveness of nab-paclitaxel + carboplatin + MPDL3280A for treatment of non-small-cell lung carcinoma (NSCLC), which is a type of lung cancer.
- Trial name
- NCT02716038
- Testing
- MPDL3280A, Carboplatin, Nab-paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Columbia University
Extensive-stage Small-cell Lung Cancer
Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
To evaluate the tolerability and safety of Low-dose radiotherapy combined with concurrent Chemotherapy, Toripalimab and Tifcemalimab in first-line treatment of Extensive-Stage Small Cell Lung Cancer, and to determine the RP2D.
- Trial name
- NCT06732258
- Testing
- Low-dose radiotherapy, Tifcemalimab injection, Toripalimab
- Sponsor
- Sichuan University
Non-small Cell Lung Cancer
Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC
The primary objective is to assess the safety and efficacy of hypofractionated radiotherapy followed by hypo-boost combined with concurrent weekly chemotherapy in unresectable LA-NSCLC patients.
- Trial name
- NCT03900117
- Testing
- split-course radiotherapy, concurrent chemotherapy
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer
FRAME-001 Personalized Vaccine in NSCLC
Despite encouraging results of programmed cell death protein -1 (PD-1) immune checkpoint inhibitor treatment combined with chemotherapy in advanced non-small cell lung cancer (NSCLC), only the minority of approximately 20% of…
- Trial name
- NCT04998474
- Testing
- FRAME-001 personalized vaccine
- Where
- 3 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Frame Pharmaceuticals B.V.
Non-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or…
- Trial name
- NCT07680790
- Testing
- Iza-bren, Osimertinib, Pemetrexed
- Where
- 204 sites in United States, Argentina and 14 more
- Volunteers
- 850 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC.
- Trial name
- LIBRA (NCT07098338)
- Testing
- Rilvegostomig, Ramucirumab, Dato-DXd
- Where
- 83 sites in United States, Australia and 10 more
- Volunteers
- 278 people
- Sponsor
- AstraZeneca
Metastatic Non-Small Cell Lung Cancer
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small…
- Trial name
- RELAY (NCT02411448)
- Testing
- Ramucirumab, Erlotinib, Gefitinib
- Where
- 106 sites in United States, Canada and 12 more
- Volunteers
- 545 people
- Sponsor
- Eli Lilly and Company
Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer
Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery
This phase II trial studies how well giving a hypofractionated boost to the primary tumor before standard chemotherapy and radiation therapy works in treating patients with stage II or III non-small cell lung cancer that cannot…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
- Trial name
- NCT02262325
- Testing
- hypofractionated radiation therapy, cisplatin, etoposide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lung Cancer
Radical Lung Radiotherapy Plus Nelfinavir
The aim of this clinical trial is to test whether the drug nelfinavir, which can increase the effectiveness of radiotherapy, can be given safely at the same time as a full dose of radiotherapy for lung cancer.
- Trial name
- NelfLung (NCT01447589)
- Testing
- nelfinavir, Radical Radiotherapy
- Where
- United Kingdom
- Sponsor
- Oxford University Hospitals NHS Trust
Non-small Cell Lung Cancer, Brain Metastases
High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
This trail is designed to assess the efficacy and safety of high dose Iconitib combined with SRS for NSCLC patients harboring EGFR mutation with brain metastases.
- Trial name
- NCT02726568
- Testing
- Icotinib, SRS
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Extensive-stage Small Cell Lung Cancer
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared…
- Trial name
- NCT04702880
- Testing
- BMS-986012, Carboplatin, Etoposide
- Where
- 39 sites in United States, Australia and 9 more
- Volunteers
- 135 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage…
- Trial name
- KANDLELIT-013 (NCT07431827)
- Testing
- Calderasib, MK-3475A
- Where
- 120 sites in Argentina, Australia and 17 more
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC
A single arm, open-label phase II is appropriate to evaluate the efficacy and safety of dose - dense combination of paclitaxel with cisplatin supported by pegfilgrastim for neo-adjuvant chemotherapy in this patient population.
- Trial name
- NCT00291850
- Testing
- Paclitaxel, Cisplatin, Pegfilgrastim
- Where
- 5 sites in Austria, Hungary and 1 more
- Volunteers
- 50 people
- Sponsor
- Central European Cooperative Oncology Group
Small Cell Lung Cancer Extensive Stage
Liposomal Irinotecan and Apatinib in ES-SCLC
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
- Trial name
- LIAES (NCT06749691)
- Testing
- Liposomal Irinotecan and Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Lung Cancer
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)
It is reported that more than 90,000 patients died of lung cancer and more than 20% of them were older than 80 years in North America.
- Trial name
- NCT01786590
- Testing
- EBUS-TBNA
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- University Health Network, Toronto
Lung Cancer - Non Small Cell
Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
Neoadjuvant immunotherapy followed by surgery has emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC).
- Trial name
- GALAXY 3 (NCT06926790)
- Testing
- Nivolumab & Ipilimumab
- Where
- China
- Volunteers
- 69 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with…
- Conditions
- Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
- Trial name
- NCT07154290
- Testing
- Ubamatamab, Marlotamig, Sarilumab
- Where
- 18 sites in United States
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
ROS1 Fusion Positive, Non Small Cell Lung Cancer
Study on the Mechanism of Acquired Resistance of Entrectinib
The goal of this observational study is to learn about the mechanism of acquired resistance in first line trearment of ROS1-positive NSCLC with entrectinib.
- Trial name
- NCT07199959
- Testing
- venipuncyure, Entrectinib
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Fudan University
Lung Cancer, Targeted Therapy
AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies
Phase II, single-arm study to assess the safety and efficacy of AZD9291 (80 mg, orally, once daily) in second-line (or later) patients with EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed…
- Trial name
- TREM (NCT02504346)
- Testing
- AZD9291
- Where
- 7 sites in Denmark, Finland and 3 more
- Volunteers
- 200 people
- Sponsor
- Oslo University Hospital
Non Small Cell Lung Cancer, Oligometastatic
The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment
This was a multi-center randomized controlled Phase II clinical trial. Patients with oligometastatic stage IV (number of distant metastases ≤ 5) non-squamous non-small cell lung cancer treated with second-line erlotinib150mg…
- Trial name
- ROLE (NCT01796288)
- Testing
- simultaneous radiotherapy, Erlotinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wu Jieping Medical Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.